About this trial
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.
Eligibility criteria
Qualifiers
adult patients (aged 18 years or order)
histologically or cytologically confirmed metastatic NSCLC previously treated with systemic therapy, supported by imaging (e.g. CT, MRI), tumor markers, or pathology reports
presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1
willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
Disqualifiers
Evidence of significantly impaired hepatic or renal function
Estimated life expectancy of less than 3 months
Trial design
Treatments tested in this trial
- 68Ga-MY6349 PET/CT
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov